[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,555
  • Shares Outstanding, K 68,370
  • Annual Sales, $ 590 K
  • Annual Income, $ -45,850 K
  • EBIT $ -47 M
  • EBITDA $ -48 M
  • 60-Month Beta 1.36
  • Price/Sales 178.71
  • Price/Cash Flow N/A
  • Price/Book 3.05

Options Overview Details

View History
  • Implied Volatility 148.48% (-115.10%)
  • Historical Volatility 97.98%
  • IV Percentile 37%
  • IV Rank 19.76%
  • IV High 483.26% on 02/09/26
  • IV Low 66.07% on 08/13/25
  • Expected Move (DTE 11) 0.4675 (31.17%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 305
  • Volume Avg (30-Day) 1,150
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 26,774
  • Open Int (30-Day) 25,970
  • Expected Range 1.0325 to 1.9675

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.16
  • Number of Estimates 6
  • High Estimate $-0.12
  • Low Estimate $-0.20
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) +23.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3500 +11.11%
on 06/03/26
2.0000 -25.00%
on 05/26/26
-0.1100 (-6.83%)
since 05/05/26
3-Month
1.3500 +11.11%
on 06/03/26
2.0550 -27.01%
on 03/10/26
-0.3700 (-19.79%)
since 03/05/26
52-Week
1.3500 +11.11%
on 06/03/26
4.5550 -67.07%
on 07/18/25
-2.1200 (-58.56%)
since 06/05/25

Most Recent Stories

More News
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​ -​ 30 mg onvansertib + FOLFIRI/bevacizumab...

CRDF : 1.5000 (-3.23%)
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.5000 (-3.23%)
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced...

CRDF : 1.5000 (-3.23%)
Cardiff Oncology: Q1 Earnings Snapshot

Cardiff Oncology: Q1 Earnings Snapshot

CRDF : 1.5000 (-3.23%)
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial  Company to provide detailed data update from Phase 2 CRDF-004...

CRDF : 1.5000 (-3.23%)
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range...

CRDF : 1.5000 (-3.23%)
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.5000 (-3.23%)
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced...

CRDF : 1.5000 (-3.23%)
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

SAN DIEGO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range...

CRDF : 1.5000 (-3.23%)
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer Appoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief Operating...

CRDF : 1.5000 (-3.23%)

Business Summary

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of...

See More

Key Turning Points

3rd Resistance Point 1.8133
2nd Resistance Point 1.7067
1st Resistance Point 1.6033
Last Price 1.5000
1st Support Level 1.3933
2nd Support Level 1.2867
3rd Support Level 1.1833

See More

52-Week High 4.5550
Fibonacci 61.8% 3.3307
Fibonacci 50% 2.9525
Fibonacci 38.2% 2.5743
Last Price 1.5000
52-Week Low 1.3500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.